Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zomedica ( (ZOMDF) ) has provided an update.
On June 10, 2025, Zomedica held its annual shareholder meeting where three key proposals were voted on. Shareholders approved the election of eight directors and the ratification of Grant Thornton LLP as the independent auditor for 2025, but did not approve the executive compensation package.
The most recent analyst rating on (ZOMDF) stock is a Buy with a $0.25 price target. To see the full list of analyst forecasts on Zomedica stock, see the ZOMDF Stock Forecast page.
Spark’s Take on ZOMDF Stock
According to Spark, TipRanks’ AI Analyst, ZOMDF is a Neutral.
Zomedica’s stock score reflects mixed financial performance with revenue growth but persistent profitability challenges. The technical analysis shows weak momentum, and the valuation is impacted by a negative P/E ratio. Despite strong earnings call highlights, increased net loss and delisting risks present concerns.
To see Spark’s full report on ZOMDF stock, click here.
More about Zomedica
Average Trading Volume: 2,393,495
Technical Sentiment Signal: Sell
Current Market Cap: $42.63M
See more insights into ZOMDF stock on TipRanks’ Stock Analysis page.